Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis
Rhea-AI Summary
Autonomix Medical (NASDAQ: AMIX) announced a Top Abstract selection at CRT 2026 for a podium presentation on March 7, 2026. The presentation will cover clinical feasibility and early outcomes for a novel transvascular RF peripheral nerve neurolysis technique that targets nerve signals for precision modulation.
The six-minute podium will appear in the Hypertension Therapies and Renal Denervation session, highlighting early clinical data and potential applicability across multiple peripheral nerve indications.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
AMIX was down 2.66% while selected peers were mixed: MOVE up 5.86%, BMRA up 1.5%, HSCS down 1.85%, HSDT down 1.49%. Momentum scanner also showed both up and down moves, supporting a stock-specific rather than sector-wide driver.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 25 | CEO communication | Positive | +8.0% | CEO Corner segment outlining publication strategy and scientific validation focus. |
| Feb 19 | Clinical data podium | Positive | +1.2% | Selection to present long-term pain mitigation data in pancreatic cancer at SSO 2026. |
| Jan 28 | Clinical data ePoster | Positive | -0.1% | Final transvascular RF ablation pain data at SIO 2026 with slight negative price reaction. |
| Jan 09 | PoC study results | Positive | +2.8% | Compelling proof-of-concept data showing rapid and durable pancreatic cancer pain relief. |
| Dec 30 | European patent grant | Positive | +8.3% | European patent EP4230133 granted for precision cardiac neuromodulation platform. |
Recent clinically focused and IP news has usually aligned with positive price reactions, with only one minor divergence.
Over the last six months, AMIX has highlighted multiple clinical and scientific milestones, including proof-of-concept pain relief data at ASCO GI and several podium or ePoster presentations on transvascular RF ablation and pain mitigation in pancreatic cancer. It also secured a European patent covering its precision nerve-targeted cardiology platform. These events often coincided with positive moves (e.g., +7.98% on Feb 25, 2026, +8.33% on Dec 30, 2025). Today’s CRT Top Abstract selection continues this pattern of academic and clinical visibility.
Regulatory & Risk Context
An effective resale shelf filed on Nov 26, 2025 registers 13,504,998 warrant-related shares for a selling stockholder. Autonomix would not receive resale proceeds but could receive up to $7.7 million in gross proceeds if the Common Warrants are exercised in cash at $0.8607 per share, with full exercise significantly increasing the share count.
Market Pulse Summary
This announcement highlights selection of Autonomix’s RF-based transvascular peripheral nerve neurolysis data as a Top Abstract for podium presentation at CRT 2026, adding to a steady stream of clinical and conference visibility. Recent history shows multiple presentations and a European patent grant supporting the platform’s profile. At the same time, investors may monitor ongoing warrant-related resale capacity of 13,504,998 shares and potential proceeds up to $7.7 million, given their implications for dilution and capital needs.
Key Terms
radiofrequency ablation medical
renal denervation medical
AI-generated analysis. Not financial advice.
THE WOODLANDS, TX, March 04, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that Nikola Cesarovic, PhD, will present clinical feasibility and outcome data at the Cardiovascular Research Technologies (CRT) 2026 Meeting, happening March 7-10, 2026, in Washington, DC.
The abstract titled, “Novel Technique For Transvascular Peripheral Nerve Neurolysis Using Radiofrequency (RF) Ablation: Clinical Feasibility And Outcomes,” will be presented during the Top Abstract Session (S194) on Saturday, March 7 from 2:18 - 2:24p ET for Hypertension Therapies and Renal Denervation session. Dr. Cesarovic will deliver a six-minute presentation, highlighting clinical feasibility and early outcomes associated with a novel RF-based approach designed to selectively disrupt peripheral nerve activity via a transvascular approach. Autonomix’s technology is engineered to identify and target specific nerve signals, potentially enabling differentiated therapeutic precision compared to conventional ablation techniques.
“This Top Abstract selection underscores the growing clinical interest in precision nerve-targeted therapies and highlights the potential of Autonomix’s platform to enable controlled, transvascular peripheral nerve modulation,” said Dr. Robert Schwartz, Co-Founder and Chief Medical Officer of Autonomix. “We believe these early feasibility findings support the broader applicability of our technology across multiple indications where peripheral nerve signaling plays a critical role.”
CRT is one of the world’s leading educational forums for interventional cardiovascular medicine, with Top Abstract podium selections representing the highest-scoring submissions based on scientific merit, innovation and clinical relevance. For more information, please visit the conference website here.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release include expectations regarding the potential effectiveness and clinical benefits of Autonomix's nerve-targeted treatments for pancreatic cancer pain and other conditions.
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 29, 2025, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
FAQ
What will Autonomix (AMIX) present at CRT 2026 on March 7, 2026?
When and where is Autonomix's (AMIX) Top Abstract podium at CRT 2026?
What is the focus of the clinical data Autonomix (AMIX) will share at CRT 2026?
How long is the Autonomix (AMIX) presentation at CRT and what does it indicate for investors?
Which CRT 2026 session includes Autonomix (AMIX)'s podium on March 7, 2026?
What clinical advantage does Autonomix (AMIX) claim for its transvascular RF technique?
